Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 14/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2830372 | 0.77 | GRM2 (0.76) | GRM2 | |
| SCHEMBL3744405 | 0.77 | MAOB (0.56) | GRM2 | |
| SCHEMBL9805030 | 0.70 | ADORA2A (0.41) | GRM2 | |
| SCHEMBL10768009 | 0.68 | MTNR1A (0.47) | — | |
| SCHEMBL2825841 | 0.67 | GRM2 (0.82) | GRM2 | |
| SCHEMBL2824384 | 0.64 | GRM2 (0.86) | GRM2 | |
| SCHEMBL11449837 | 0.63 | GRM2 (0.70) | GRM2DRD4 | |
| SCHEMBL18471240 | 0.63 | CYP2D6 (0.44) | — | |
| SCHEMBL7708537 | 0.63 | TDP1 (0.57) | DRD4TDP1FGFR1SRC | |
| Dimethylamine SCHEMBL7289694 | 0.62 | TDP1 (0.85) | GRM2HRH3TDP1FGFR1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292241-A1 | 3,5-SUBSTITUTED-1,3-OXAZOLIDIN-2-ONE DERIVATIVES | GRM2, GRM3, GRM1 | GRM2 1/4885HRH3 519/4885DRD4 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.